Mostrar el registro sencillo del ítem
Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
| dc.contributor.author | Boneu Yepez, Deiby | spa |
| dc.contributor.author | Barragán Montiel, Robinson | spa |
| dc.contributor.author | Arroyo Carrascal, Dayana | spa |
| dc.date.accessioned | 2021-07-15 00:00:00 | |
| dc.date.available | 2021-07-15 00:00:00 | |
| dc.date.issued | 2021-07-15 | |
| dc.identifier.issn | 2215-7840 | |
| dc.format.mimetype | application/pdf | spa |
| dc.language.iso | spa | spa |
| dc.publisher | Universidad de Cartagena | spa |
| dc.relation.ispartofjournal | Revista Ciencias Biomédicas | spa |
| dc.rights | Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021 | spa |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | spa |
| dc.source | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3500 | spa |
| dc.subject | Heart failure | eng |
| dc.subject | Valsartan | eng |
| dc.subject | Neprilysin | eng |
| dc.subject | Atrial natriuretic factor | eng |
| dc.subject | Angiotensin-converting enzyme inhibitors | eng |
| dc.subject | Insuficiencia Cardíaca | spa |
| dc.subject | Valsartán | spa |
| dc.subject | Neprilisina | spa |
| dc.subject | Péptido natriurético atrial | spa |
| dc.subject | Inhibidores de la enzima convertidora de angiotensina | spa |
| dc.title | Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca. | spa |
| dc.type | Artículo de revista | spa |
| dc.title.translated | Association between valsartan and neprilisin inhibitors in the management of heart failure. | eng |
| dc.identifier.doi | 10.32997/rcb-2021-3500 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.identifier.eissn | 2389-7252 | |
| dc.identifier.url | https://doi.org/10.32997/rcb-2021-3500 | |
| dc.relation.bitstream | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3500/2949 | |
| dc.relation.citationedition | Núm. 3 , Año 2021 | spa |
| dc.relation.citationendpage | 206 | |
| dc.relation.citationissue | 3 | spa |
| dc.relation.citationstartpage | 198 | |
| dc.relation.citationvolume | 10 | spa |
| dc.relation.references | Ulate-Montero G, Ulate-Campos A, Actualización en los mecanismos fisiopatológicos de la insuficiencia cardiaca, AMC, Vol 50 (1), enero-marzo 2008. | spa |
| dc.relation.references | De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, Capitulo 4, 2010. | spa |
| dc.relation.references | De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, capitulo 3, actualizado en 2015. | spa |
| dc.relation.references | Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295. | spa |
| dc.relation.references | Dickstein K, Cohen-Solal A, Filippatos A. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008), Rev Esp Cardiol. 2008; 61(12): 1329.e1-1329.e70. | spa |
| dc.relation.references | GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858. | spa |
| dc.relation.references | Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8): 1342-1356. | spa |
| dc.relation.references | Jaramillo C, et al., Consenso Colombiano para el diagnóstico y tratamiento de la insuficiencia cardiaca crónica, sociedad colombiana de cardiología y cirugía cardiovascular, 1 edición, inversiones tecnograficas S.A.S., Bogotá, noviembre de 2014. | spa |
| dc.relation.references | Tousignant M, Mbuila Mampuya W, Telerehabilitation for patients with heart failure, Cardiovasc Diagn Ther 2015; 5(1): 74-78. | spa |
| dc.relation.references | Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker et al, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal June 8, 2016. | spa |
| dc.relation.references | Song W, Wang H, Wu Q. Atrial Natriuretic Peptide in Cardiovascular Biology and Disease (NPPA). Gene. 2015; 569(1): 1-6. | spa |
| dc.relation.references | Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295. | spa |
| dc.relation.references | Barrett AJ, Rawlings ND, O’Brien EA. The MEROPS database as a protease information system. J Struct Biol 2001;1 34: 95–102. | spa |
| dc.relation.references | Nalivaeva, N. N., Zhuravin, I. A., & Turner, A. J. (2020). Neprilysin expression and functions in development, ageing and disease. Mechanisms of ageing and development, 192, 111363. https://doi.org/10.1016/j.mad.2020.111363 | spa |
| dc.relation.references | Salazar, J., Rojas-Quintero, J., Cano, C., Pérez, J. L., Ramírez, P., Carrasquero, R., Torres, W., Espinoza, C., Chacín-González, M., & Bermúdez, V . (2020). Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?. Current cardiology reviews, 16(1), 25–35. https://doi.org/10.2174/1573403X15666190625160352 | spa |
| dc.relation.references | Chaves G, Diaztagle J, Vargas V, Mejía M, Sprockel J, Hernández J, Cumplimiento de guías en pacientes hospitalizados con falla cardiaca ¿Cómo estamos? Acta Médica Colombiana 2014, 39 (Enero-Marzo). | spa |
| dc.relation.references | Von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 144(1): 41–49 (2014). | spa |
| dc.relation.references | García S, Parodi R, Tos y angioedema en pacientes tratados con inhibidores de la enzima convertidora de la angiotensina siempre es culpable la medicación, Rev. argent. cardiol. vol.79 no.2 Ciudad Autónoma de Buenos Aires mar./abr. 2011. | spa |
| dc.relation.references | Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015; 65: 1029–1041. | spa |
| dc.relation.references | Grothusen A, Divchev D, Luchtefeld M, Schieffer B. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva Cardioangiol. 2009 Dec; 57(6): 773-85. | spa |
| dc.relation.references | Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018). Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological reviews, 98(3), 1627– 1738. https://doi.org/10.1152/physrev.00038.2017 | spa |
| dc.relation.references | Kinoshita H, Kuwahara K, Nishida M, Jian Z, Rong X, Kiyonaka S, Kuwabara Y, Kurose H, Inoue R, Mori Y, Li Y, Nakagawa Y, Usami S, Fujiwara M, Yamada Y, Minami T, Ueshima K, Nakao K. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-Asignaling in the heart. Circ Res. 2010 Jun 25; 106(12): 1849-60. | spa |
| dc.relation.references | Gaggin H.K., Januzzi J.L. Jr. (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832: 2442–2450. | spa |
| dc.relation.references | Giuseppe Lippi, Fabian Sanchis-Gomar, Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge, International Journal of Cardiology 219 (2016) 111–114. | spa |
| dc.relation.references | Pacheco-Quinto J,Herdt A,Eckman CB,Eckman EA. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J Alzheimers Dis. 2013; 33 Suppl 1: S101-10. | spa |
| dc.relation.references | Galli A, Lombardi F, Neprilysin Inhibition for Heart Failure, The new england journal of medicine, nengljmed 371;24 nejm.org december 11, 2014. | spa |
| dc.relation.references | McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11): 993-1004. | spa |
| dc.relation.references | to S, Satoh M, Tamaki Y., Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, The Japanese Society of Hypertension, Hypertension Research (2015) 38, 269–275. | spa |
| dc.relation.references | Adriaan A. Voors et al, Renal effects of neprilysin inhibitor LCZ696 in patients with HFpEF, European Journal of Heart Failure © 2015 European Society of Cardiology, European Journal of Heart Failure (2015) 17, 510–517. | spa |
| dc.relation.references | McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin- converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15: 1062–1073. | spa |
| dc.relation.references | Sadayoshi Ito et al, Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, Hypertension Research (2015) 38, 269–275. | spa |
| dc.relation.references | Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, Clarke A, Biggerstaff F, Hillier C, McMurray JJ. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2014 Feb; 32(1): 13-8. | spa |
| dc.relation.references | Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015:11 283–295. | spa |
| dc.relation.references | Akshay S. Desai et al, Influence of Sacubitril Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization, JACC VOL. 68, NO.3, 2016, JULY 19, 2016: 241–8. | spa |
| dc.relation.references | Dargad RR, Prajapati MR, Dargad RR, Parekh JD. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.Indian Heart J. 2018; 70 Suppl 1(Suppl 1): S102-S110. | spa |
| dc.relation.references | Ganesananthan S, Shah N, Shah P, et al. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart. 2020; 7(2): e001305. | spa |
| dc.relation.references | Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Jan 4: S0735-1097 (20) 37867-0. | spa |
| dc.relation.references | Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019 Aug; 21(8): 998-1007. | spa |
| dc.relation.references | Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep; 18(9): 1193-202. | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.creativecommons | Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
| dc.type.content | Text | spa |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.local | Journal article | eng |
| dc.type.redcol | http://purl.org/redcol/resource_type/ARTREV | spa |
Ficheros en el ítem
| Ficheros | Tamaño | Formato | Ver |
|---|---|---|---|
| Rev Cienc Biomed-3500.pdf | 465.3Kb | application/pdf | Ver/ |
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021
